innovative and naturally-sourced active … · director of medicinal chemistry merck has brought 2...

ANTIBIOTICS

ANTIFUNGALS

BIOACTIVE COMPOUNDS

ANTIOXIDANTS

PIGMENTS

NUTRITIONAL ADDITIVES

COLORING AGENTS

ANTIOXIDANTS

HEALTH NUTRITION COSMETICS

INNOVATIVE AND NATURALLY-SOURCED ACTIVE MOLECULES

FOR HEALTH, NUTRITION AND COSMETICS

STRATEGIC UPDATE DEINOVE

AGENDA

Introduction

• Emmanuel Petiot - CEO

Strategy antibiotics

• Georges Gaudriault - CSO

Acquisition of Morphochem


Achievements Cosmetics

• Coralie Martin - Marketing

Conclusion


2

DEINOVE

BIOTECH PLATEFORM

3

DEINOVE

Profile

6,000PROPRIETARY

STRAINS

1CUTTING-EDGE

TECHNOLOGICAL

PLATFORM

NUTRITION

Anti-oxidants (carotenoids)

Coloring agents

Nutritional additives…

COSMETICS

Anti-oxidants

Healing, anti-inflammatory…

compounds

Pigments …

HEALTH

Antibiotics

Antifungals

HARNESS THE POTENTIAL OF OUR BIOLOGICAL DIVERSITY

COMPOSED OF DEINOCOCCUS AND OTHER OF RARE MICROORGANISMS

TO PROVIDE INNOVATIVE COMPOUNDS

FOR HIGH VALUE MARKETS

55HIGHLY-SKILLED

STAFF

1,500 m2

LAB FACILITIES

130PATENT

APPLICATIONS

4

A COLLECTION OF 6,000 STRAINS

Draw from the diversity of the living world to innovate

4 years of harvesting in

numerous hostile environments: hot springs, volcanoes, lagoons, glaciers,…

1,200 collection points

A patented selection method using UV radiation

6,000 strains

available

Brevibacillus thermoruber

Anoxybacillus kamchatkensis Aeromonas sp.

Deinococcus geothermalis

5

A CUTTING-EDGE TECHNOLOGICAL PLATFORM

Realize the full potential of the strain collectionDesign molecules with optimal performances

COLLECTION AND

AUTOMATED PRODUCTION

OF EXTRACTS

ANALYTICAL

PLATFORM

SCREENING

In vitro

In cellulo

Fast identification of

features of interest

FERMENTATION,

EXTRACTION, PURIFICATION

34 instrumented reactors

Optimization of production environment

Pre-industrial production

AUTOMATED GENETIC

ENGINEERING

Automate + proprietary software

High throughput platform

Machine learning

MOLECULE

OF INTEREST

6

BIOINFO

Gene miningBIO

INF

OR

MA

TIC

S

Me

tagénom

ics

MARKETS

Producing high value compounds

57 B$ (Future Market Insights & BCC)

20 B$(Markets and Markets)

22 B$(Kline)

3

NUTRITION

Anti-oxidants (carotenoids)

Coloring agents

Nutritional additives…

2

COSMETICS

Anti-oxidants

Healing, anti-inflammatory…

compounds

Pigments …

1

HEALTH

Antibiotics

Antifungals

7

BUSINESS MODEL

Funding & revenues

EQUITY

NON-DILUTIVE FUNDING

R&D CONTRACT REVENUES

• R&D COLLABORATIONS

• TECHNOLOGY LICENCING

INDUSTRIAL DEALS

• PROPRIETARY COMPOUNDS

• DIRECT MARKETING, TOLLING, STRATEGIC DISTRIBUTION

DIRECT SALES

8

A REINFORCED SKILLED TEAM

In pharma development, from discovery to market

Emmanuel PetiotCOO

Novozymes Europe

Sébastien EnaultDirector BD Eligo Biosciences

Georges GaudriaultCSO MedinCell

Christophe ParsyDirector of Medicinal chemistry Merck

Has brought 2 anti-viral drugs to clinic

Jozsef AszodiDirector R&D Sanofi, Inventor of Avibactam

Denis CarniatoMedicinal chemistry manager

Dominique Le BellerCo-founder of Novexel acquired by Astrazeneca (475M$) - 3

antibiotics developed o/w Ketek®

9

A SPECIALIZED BOARD OF DIRECTORS

Proven experience in health and biotech sector

10

Philippe PoulettyFounder of Truffle Capital

Founder of SangStat acquired by Genzyme for 600M$

Hervé BraillyCo-founder & Chairman of Supervisory Board at Innate

Pharma

Charles Woler, ChairmanFormerly Chairman and CEO of Roche France

Chairman of Genfit & GSK Europe

Yannick PlétanChief medical officer, global Head of development and R&D strategy

For Pierre Fabre, Sanofi and Roche

Vincent JarlierHead of Bacteriology Department, Pitié-Salpétrière Hospital

Founder & President of National observatory for antimicrobial resistance (ONERBA) Member of steering committee of European Study Group for Antibiotic Resistance Survey (ESGARS) of ESCMID

and European Antimicrobial Resistance Survey System (EARS-Net)

STRATEGY ANTIBIOTICS

Georges GAUDRIAULT – CSO

ANTIMICROBIAL RESISTANCE

The process of antibiotic resistance

12

Inadequate antibiotic treatment:

- Kill the bacteria that caused infection

- Resistant bacteria survive

Resistant bacteria can become predominant

and impede recovery

Bacteria causing serious diseases

that are increasingly hard to cure

Urban

people

2006

2016

+ 8.6 %

In 2015

4th

Consuming country

in Europe

ANSES 2017

Consumption of antibiotics in France

Antibiotic 1 Antibiotic 2

Find new antibiotic structures to fight

against resistant strains

Ensure sustainable treatment options

ANTIMICROBIAL RESISTANCE

A global health challenge

«Antimicrobial resistance is a slow-motion tsunami that must be managed with the

utmost urgency. Only two new classes of antibiotics have reached the market in the last

50 years. With few replacement products in the pipeline, the world is heading towards a

post-antibiotic era in which common infections will once again kill. »

Dr Margaret Chan, Director-General of the WHO, Sept.2016

➤URGENT NEED TO FIND NOVEL ANTIBIOTIC STRUCTURES

TO FIGHT MULTI-RESISTANT PATHOGENS

Antibiotic resistance kills each year

700,000 people

In 22 countries.

10 000 000700 000

8 200 000

1 500 000

1 400 000

1 200 000

130 000

110 000

60 000

Résistance auxantimicrobiens

Cancer

Diabètes

Diarrhée

Accidents de la route

Rougeole

Choléra

Tétanos Aujourd'hui

2050

And this numbers

will grow exponentially

13

ANTIMICROBIAL MARKET

A reviving market

➢ Recent acquisitions/deals involving biotechs/big pharmas and public institutions

• Novexel / AstraZeneca = 500 M$

• Polyphor / Roche = 400 M$

• Cubist / Merck = 9.5 B$

• Adapsyn / Pfizer = 162 M$

• Wrap Drive Bio / Roche = 387 M$

• GSK / Barda = 200 M$

• AstraZeneca / Barda = 220 M$

➢ Support to drug development

• US : GAIN (Generating Antibiotics Incentives Now)

• 5-year market exclusivity post patent expiration (QIDP)

• FDA : fast-track registration procedure

➢ Public funding

• Bpifrance

• European Investment Bank

• UE : Innovative Medicines Initiative

• US : BARDA (Biomedical Advanced Research and Development Authority)

• CARB-X / Wellcome Trust

• NIAID

• Gates foundation…

14

40,6 44,7

12,118,1

2015 2020

Global market od antibiotics and antifungals (B$)

Antibiotics Antifungals

DEINOVE IN ANTIBIOTICS

Strategy and Action plan

Identify, develop and bring to market novel antibiotic and antifungal structures to address the global heath challenge of microbial resistance

Explore the biodiversity of the Deinove strain collection

Enhance the potential of the engineering platform

Implement a fully automated and integrated approach

Expand the portfolio with molecules under development

AGIRANTIBIOTIQUES CONTRE LES GERMES INFECTIEUX RÉSISTANTS

2009-2016

2016-2017

2017-2022

2018-20…

Acquisition

License optionCollaboration to explore new strains

15

Now holds 100% of

DEINOVE IN ANTIBIOTICS

Molecule portfolio

16

Preclinical Phase I Phase II Phase III

MCB3837 (Morphochem) – Severe Clostridium difficile infections

NBTI (RedX) – HAP/cUTI/cIAI (Acinetobacter baumanii – Pseudomas aeruginosa)

DNB102 – SSTI, Gram+ bacterial infections

AGIR

AGIR: Antibiotics against Resistant Infectious aGents

17

An ambitious project to discover and develop new antibiotics from natural sources

Developing the

discovery platform

Implementing

lead

optimization

and process

development

Production of

molecule with

optimal

performances

« AGIR » Antibiotiques contre les Germes Infectieux Résistants

Bacteria Antibiotics

Identify novel antibiotic structures from rare or untapped bacterial strains, by

developing new methods to collect, culture, screening, optimization and evaluation;

and thus contribute to create new therapies that answer the medical urgency

AGIR: Antibiotiques contre les Germes Infectieux Résistants

18

An ambitious project to discover and develop new antibiotics from natural sources

Microorganisms like bacteria are among the most effective living producers of antibiotics

Many antibiotics are sourced from the living world

• ex: penicillin, the 1st antibiotic discovered

Untapped potential so far

• Discovery of novel antibiotics has been limited by the almost exhaustive exploitation of the same strains

➤ Explore new bacteria to access novel chemical structures

The AGIR Program

19

At a glance

Build an automated Discovery platform dedicated to rare bacteria

• 10 000 new strains• New methods for discovery

(collection, culture and selection) and optimization

Identify new antimicrobials

Generate 4 leads active on G+/G– bacteria

Bring new molecules to preclinical and clinical stages

Discover and develop novel antimicrobial classes (antibiotics and antifungals)

Bring efficient solutions for the fight against resistant infectious diseases

Put France at the forefront of global innovation in antibiotics

Multiply leads

Develop the drug candidates portfolio

Generate revenuevia license deals

OBJECTIVE AMBITIONEXPECTED RESULTS

AGIR: Antibiotiques contre les Germes Infectieux Résistants

20

Supported by Bpifrance

T0 01/11/2017

End 31/10/2022

60 months

5 Key milestones

AGIR Project

AGIR Program: explore new strains

21

The Naicons bacterial collection

NAICONS

➢ Italian Biotech researching for new antibiotics

➢ Bacterial collection of 45,000 strains selected from :

• Uncommon morphology

• Peculiar physiology

• Unusual origin

➢ Portfolio of 5 candidates, o/w 1 in Phase II clinical development

➢ Limited resources

COLLABORATION AGREEMENT

DEINOVE Technological Platform

+400 strains selected

from the Naicons collection

=Accelerated Characterization of the

antibiotic potential of strains

➢ In case of a strain of interest is discovered, possible acquisition

• via commercial license,

• or in full ownership

DNB101: the 1st des leads nouvelle génération de Deinove

22

Confirms the platform potential:Is produced by a strain that was previously studied by others that did not identify antibiotic activity

Novel chemical

structureActivity against dangerous

antibiotic-resistant bacteria,

identified as a priority by

public health authorities

Ongoing tests:

efficacy,

pharmacology…Next step: develop the

new lead DNB102

Two patent

applications published

Strains MIC90 (µg/mL) Strains MIC90 (µg/mL)

S. aureus [MSSA & MRSA] 2 C. difficile 0.125S. epidermidis [MSSA & MRSA] 0.5 P. acnes 0.03E. faecium [Vancomycin S & R] 0.5 E. coli >4E faecalis >4 P. aeruginosa >4S. pneumoniae 0.125 C. albicans >4

Accelerated development strategy

23

Acquisition of first-in-class antibiotics

22 March 2018 : Accord d’Option de Licence avec RedX Pharma• License option exercisable from end of 2018• Novel Bacterial Topoisomerase Inhibitor (NBTI) – novel class of

antibiotics, about to enter preclinical development• Targeting Gram negative infections caused by priority pathogens• Program eligible for non dilutive financing initiatives

13 April 2018 : Acquisition of Morphochem• Acquisition of MCB3837, a drug ready for phase II• Targeting severe Clostridium difficile infections (CDI), administered

intravenously• Has obtained QIDP designation and Fast Track status from FDA• Acquisition of Biovertis and its subsidiary Morphochem• TVM Capital becomes shareholder of DEINOVE


24




13 April 2018 : Acquisition of Morphochem• Acquisition of MCB3837, a drug ready for phase II• Targeting severe Clostridium difficile infections (CDI),

administered intravenously• Has obtained QIDP designation and Fast Track status from FDA• Acquisition of Biovertis and its subsidiary Morphochem• TVM Capital becomes shareholder of DEINOVE

NBTI, compounds active against Gram negative bacteria

25

License option agreement with RedX Pharma

Novel antibiotic class

against Gram negative bacteria

as a substitute for

fluoroquinolones: same target /

different site of action

→ no cross resistance

Eligible for QIDP designation

and Fast Track status

Other targeted

indications:

• Urinary tract

infections

• Intra-abdominal

infections

Initial Indication targeted:

Hospital-acquired pneumoniae (HAP)

• Over 740,000 recorded cases of HAP in the 6 MM

• ~11.5% of the most common Gram negative pathogens

associated with HAP are multidrug resistant

• Expected revenues of about US$3.8 bn by 2020

Preclinical stage

• Efficacy validated by several

in vivo studies

• Acceptable safety profile

• Optimization in progress

➢ « Serious threats » according to the CDC

➢ Among the 12 deadliest pathogens for humans according to WHO


26




13 April 2018 : Acquisition of Morphochem• Acquisition of MCB3837, a drug ready for phase II• Targeting severe Clostridium difficile infections (CDI), administered

intravenously• Has obtained QIDP designation and Fast Track status from FDA• Acquisition of Biovertis and its subsidiary Morphochem• TVM Capital becomes shareholder of DEINOVE

MCB3681 / MCB3837

27

Clostridium difficile infections, a major pathology

Clinical symptoms

• Diarrheas

• Abdominal pains

• Vomiting

• Peritonitis

• Sepsis

Mortality

40% of patients with CDI suffer from a severe form35-50% : mortality rate of patients with severe complicated CDI (megacolon, perforation)

Recurrence

• ~20% readmission within 30 days

•Steadily increasing, related with the development of highly virulent strains

CDC : Centers for Disease Control and Prevention (

Clostridium difficile infections (CDI)

28

A growing pathology

USA

29,300 deaths/year

1st agent cause of

HAI* (12.5%)

Estimated economic burden:

$ 1.2 / 4.8 B / year

EUROPE

3,700 deaths/year

8th agent cause of

HAI* (5,4%)

Estimated economic burden:

€3.0 B / year

0

100 000

200 000

300 000

400 000

500 000

600 000

700 000EU

USA

CDI incidence and projections

Incid

ence

2012 2021

845.000

364481

411

662

1.073.000

+27%

Sources: Decision Resources: Treatment Trends C. diff. Infections (EU) 2013. Davies et al. LID 2014. Lessa et al., 2015. Morphochem.

➢ Ageing population

• In 2050, + 135 millions Europeans will be over 65

➢ Increasing number of people in long term care (LTC) facilities

➢ Increasing number of beds per hospital/ LTC facility

➢ Increasing awareness for underdiagnoses of CDI

• absence of clinical suspicion,

• suboptimal diagnostic methods, and

• unreported cases due to embarrassment nature of illness for both patients and treatment facilities

HAI : hospital acquired infections

1st pathogen causing

hospital acquired

infections

Clostridium difficile infections (CDI)

29

May Cause Life Threatening Diarrhea

Diagnostic findings Healthy colon Pseudo-membranous colitis

Pancolitis / Ileus Méga-côlontoxique

Severity Mild Moderate Severe Complicated

Clinical symptoms • Mild diarrhea• Afebrile status• Mild abdominal

discomfort or tenderness• No notable lab

abnormalities

• Moderate non bloody diarrhea

• Moderate abdominal discomfort or tenderness

• Nausea with occasional vomiting

• Dehydration• WBC count

>15,000/mm3• Blood urea nitrogen or

creatinine levels above baseline

• Severe or bloody diarrhea

• Severe abdominal pain• Vomiting• Acute kidney injury• Temperature >38.9◦C• WBC count

>20,000/mm3• Serum albumin level <2.5

g/dL

• Peritonitis• Respiratory distress• Hemodynamic instability• Sepsis

Treatment • Oral Metronidazole • Oral Metronidazole• Oral Vancomycin

• Oral or nasogastric Vancomycin ± IV Metronidazole

• Oral or nasogastric Vancomycin ± IV Metronidazole

• Colectomy

Initial Indication

Toxic megacolon

Sources : Leffler et al., NEJM 2015; 372. Luebbert et al., DAE Int 2014; 111.;

https://de.wikipedia.org/wiki/Koloskopie (accessed July 22, 2015).

MCB3681 / MCB3837

30


1st line treatment of severe

Clostridium difficile infections

(IV administration)

Treatment by intraveinous injection

• Severe cases: oral treatments

are not effective (colitis,

intestinal paralysis…)

• No effective treatment by IV

→ IV administration of MCB3837

could bring a new effective

therapeutic option

Fast Track Status

& QIDP granted

Ready to enter Phase II

• Green light from FDA

• Tolerability tested in

Phase I (3 Phases I

including over 100

patients)

• Significant efficacy

against C. difficile

isolates, irrespective of

their virulence

MCB3681 / MCB3837, targeted efficacy

31

Activity specifically targeted toward Clostridium difficile, no changes in microbiota

➢ High concentrations of the substance have been found in feces of healthy volunteers (Fig. 3), with a significant antibacterial effect against Clostridia other Gram positives species (Fig. 1).

➢ The Gram-negative intestinal flora including bacteroides, known to provide resistance to colonization by dangerous pathogens, was not affected by the treatment (Fig. 2).

Phase I trial on 12 healthy subjects (Karolinska Institutet) - Rashid M et al., Nord CE: Ecological impact of MCB3837, IJAA 44 (2014) 44, 125-130

MCB3681 / MCB3837, targeted efficacy

32

Efficacy vs. competitive drugs

High in vitro activity against C. difficile

• Activity demonstrated against

114 clinical isolates of C. difficile

• Superior activity compared to

Vancomycin, Metronizadole,

Fidaxomicin and other comparators

ACQUISITION OF MORPHOCHEM

Emmanuel Petiot - CEO


➢ Acquisition of 100% of Biovertis shares through a contribution in kind of new DEINOVE shares

• From shareholders, option and right holders,

• TVM Capital Life Science (82.98%) will receive 50,001 DEINOVE shares to which will be attached 8 million warrant (Bons d’attribution d'actions, BAA)

• Representing €900,001.80 (€1.80 per share, the closing share price at 17/01/18, the last trading day preceding the signature of a letter of intent between the parties). No cash payment will be made by DEINOVE.

• The 500.001 new shares issued as part compensation for this contribution will represent 4.06% of DEINOVE's capital after the transaction.

➢ Operation subject to the approval of the General meeting of 23 May,2018

Terms (1/2)

34

Acquisition de Morphochem

➢ A deal designed to share risks and success• The exercise of the 8 millions BAA the exercise of the warrants is conditional on

achieving highly value creating milestones✓ 500,001 new shares upon the beginning of the Project’s next clinical trial (first

patient in);

✓ 2,300,000 new shares upon the start of the Project’s phase IIb/III pivotal trial or phase III (first patient in);

✓ 2,300,003 new shares upon the end of the Project’s positive phase IIb/III pivotal trial or phase III;

✓ 1,399,998 new shares upon the FDA acceptance of regulatory filing for the first marketing approval of the Project;

✓ 1,499,998 new shares upon the first marketing approval of the Project.

➢ TVM Capital, a new shareholder for DEINOVE

• 6-month lock-up agreement on the newly created shares• TVM Capital shall have the right to nominate one representative only to the board

of directors of DEINOVE (as long as the contributors collectively hold at least 5% of DEINOVE shares).

➢ DEINOVE has made a commitment to have sufficient financial resources to ensure its going concern as well as that of its subsidiaries. TVM Capital has committed to substantially contribute to its future financing needs.

Terms (2/2)

35

ACHIEVEMENTS COSMETICS

Coralie Martin - Marketing

Phyt-n-resist, an asset 100% developed by DEINOVE

The first pure colorless carotenoidCOMMERCIAL LAUNCH

APRIL 2018

➢ Phytoene, colorless carotenoid and the precursor of all carotenoids

• A substance ensuring the cell protection (plants or skin cells)from oxidative stress

• Unlike plants, skin cannot synthesize Phytoene

➢ Phyt-N-Resist, lthe first pure phytoene

• until now, no available process to obtain of pure Phytoene

• Plant extraction processes only provide a mix of carotenoids, at low concentration, and with varying degrees of stability and colors

37


A truly innovative and differentiated anti-ageing ingredient

Step back in time by tapping into the first forms

of life on Earth

Deinococcus , a “hyper resistant” micro-organisms , adapts to some of the Earth’s most extreme conditions (extreme pressure, heat, cold, dryness, pH, radiation).

DEINOVE is the sole company harnessing these extraordinary abilities and apply them to formulations in order to achieve results similar to those seen in nature.

This research will allow the skin to better adapt to environmental changes.

BIOEXTRACTION 100% pure moleculeConcentrated

MULTIPLE APPLICATIONSHigh antioxidative power

Healing propertiesUV Protection

ACTIVE INGREDIENTInnovative Carotenoid

PATENTED TECHNOLOGY

SCIENTIFIC PROOF In vitroEx vivoIn vivo

PROCESS DE PRODUCTIONEnvironmentally friendly: vegetable raw materials, fermentation-derived, green oil…Reproducible

38


Allegations and proof of efficacy

ENHANCED SKIN REGENERATION

FOR GREATER YOUTH RESILIENCE

AND VISIBLE ANTI-AGING BENEFITS

Firmness (x2) - Elasticity (x3, as of 28 days) - Radiance

TARGETED ANTIOXIDANT PROTECTION

Ex vivo tests: – 80% lipid oxidation vs. untreated explants In vivo tests: DHA test: promotes complete skin regeneration after 14 days compared to 20 days under natural conditions

In vitro : accelerates skin repair

Clinical tests : wrinkles depth reduced by 17% after 56 days

39

Two other active ingredients developed in collaboration

One of them launched on the market since April 2018

A major player in production and distribution of natural ingredients produced with biotechnologies

Around 100 active ingredients produced from biodiversity and marketed to cosmetic brands in 30 countries

Part of the US group Hallstar

Proprietary technology of Oleo-Eco-Extraction

Already more than 20 active ingredients marketed to cosmetic brands in France and abroad

APRIL 2018

PLANNED END 2018

40

Other opportunities for collaboration

A catalogue of qualified active extracts

Antioxidant

Anti-aging

UV protection…

Healing

Anti-aging

Damaged skin…

Lipid storage

Plumping effect

Moisturizing effet…

Anti-inflammatory

Sensitive/irritated skin

Post-operative skin care…

Lipolysis

Slimming

Anti-cellulite…

Whitening

Lightening/radiance

Anti-spot…

Dozen of DEINOVE’s strains with confirmed properties

41

Other opportunities for collaboration

A catalogue of qualified active extracts

Strain 4478

Allegations

Features

✓ Anti-ageing

✓ Sensitive skin care

✓ Damaged skin care

✓ Post operative treatment

Innovative and natural ingredient

Anti-inflammatory effect and strong healing power

Dose effect

✓ Source: French Polynesia

✓ Sample type: basalt flows

42

CONCLUSION

Emmanuel Petiot - CEO

MAJOR ADVANCES ON EVERY MARKET

2017

44

JAN • 1st new antibiotic structure patented

• Deinobiotics becomes a fully-owned subsidiary

MAR • Screening of 430 strains for applications in cosmetics, health and nutrition: dozens of hits

identified (anti-oxidant, anti-inflammatory, healing, activity on lipid metabolism)

• Partnership with Greentech to co-develop and market a first cosmetic ingredient by end of

2018

APR • Partnership with Avril: Phase II successfully completed - Effectiveness and bioavailability of

the ingredients developed by Deinove validated => moving towards assessment of the

technical-economic criteria and preparing for industrial production

MAY • 1st patent in animal nutrition, issued in China

JUL • Carotenoids: 1 molecule selected for production on an industrial scale in 2018 and

characterized (antioxidant and healing properties, safety), yield optimized on lab-scale =>

moving towards validation of the industrial process conditions and selection of

subcontractors

SEPT • AGIR Antibiotics project granted 14.6M€ by ‘Invest for the Future’ Program

OCT • Carotenoids: confirmation of the commercial launch during the 1st half of 2018, targets

anti-aging skincare

DEC • Launch of the carotenoid industrial production

MAJOR ADVANCES ON EVERY MARKET

2018

45

JAN • Partnership is cosmetics with OLEOS-HALLSTAR

FEV • Production of the first industrial batches of Phytoene

MAR • R&D license agreement with NAICONS

• License option on the NTBI preclinical program of REDX

AVR • Commercial launch of Phyt-N-Resist

• Commercial launch of HEBELYS by GREENTECH

• Announcement of the acquisition of the MCB3681 / MCB3837 clinical program and of the

MORPHOCHEM company

To be continued…

THE DEINOVE SHARE EVOLUTION

46

And capital breakdown

11,5%

2,4%

5,3%

80,8%

Funds managed by Truffle Capital

Scientific founders

Management & Board members

Free float

(base diluée)

Market capitalization: 42 m€

Share price: 3,6 €

Average volume / 52 weeks: 125,000 shares/day

FINANCIAL DATA

➢ FY Group loss: -7.3 m€

• Vs. -6.3 m€ in 2016, mainly due to the full integration of the Deinobioticssubsidiary in the consolidated accounts

➢ Group cash & equivalent (net): +4.9 m€ (vs. +9.3 m€ end of 2016)• Cash out : operating expenses (-8.1m€) ; Capex/leasing (-1.8m€)• Cash in : revenue from collaborative contracts +0.2m€ ; Tax credit +1.4m€ ;

disposal of Carbios shares +0.5m€ ; Equity line +2.8m€ ; Integration of Deinobiotics +0.6m€ ; grants and repayable advances +0.1m€, BSA/BCE +0.1m€

➤ Sufficient resources to finance the activities, within the current configuration of projects, until the end of 1st quarter of 2019, without having to activate the 4th tranche of the equity line.

47

FY 2017

CONTACTS

48

Montpellier, FRANCECAP SIGMAZAC Euromédecine II1682 rue de la Valsière34790 GRABELSwww.deinove.com

Emmanuel PETIOTCEOTel.: + 33 6 13 80 25 [email protected]

Coralie MARTINCommunication, Marketing and Investor relations managerTel.: + 33 4 48 19 01 [email protected]

innovative and naturally-sourced active … · director of medicinal chemistry merck has brought 2...

Documents